The American Journal of Surgery
Volume 186, Issue 4 , Pages 383-385, October 2003

Postoperative ultrasound-guided percutaneous placement of a new breast brachytherapy balloon catheter

Presented at the Fourth Annual Meeting of the American Society of Breast Surgeons, Atlanta, Georgia, April 30–May 4, 2003

  • Victor J Zannis, M.D.

      Affiliations

    • Breast Care Center of the Southwest, 2525 West Greenway Rd., Suite 130, Phoenix, AZ, 85023, USA
    • Corresponding Author InformationCorresponding author. Tel.: +1-602-942-8000; fax: +1-602-942-8025.
  • ,
  • Lise C Walker, M.D.

      Affiliations

    • Breast Care Center of the Southwest, 2525 West Greenway Rd., Suite 130, Phoenix, AZ, 85023, USA
  • ,
  • Belinda Barclay-White, M.D.

      Affiliations

    • Breastnet, Scottsdale, AZ, USA
  • ,
  • Coral A Quiet, M.D.

      Affiliations

    • Foundation for Cancer Research and Education, Arizona Oncology Services, Scottsdale, AZ, USA

Received 3 June 2003; received in revised form 21 June 2003

Abstract 

Background

The optimal technique and timing for the implantation of a recently developed breast brachytherapy balloon catheter (MammoSite; Proxima Therapeutics, Alpharetta, Georgia) have not been well defined. We hypothesized that placing this postoperatively, utilizing percutaneous ultrasound-guided placement, would be preferable.

Methods

Patients who met eligibility requirements for breast brachytherapy were implanted with the MammoSite device utilizing percutaneous ultrasound-guided technique. Additionally, to study optimal timing, a historical cohort of patients operated upon for breast cancer by two of the authors were analyzed to compare the intraoperative and postoperative candidacy for MammoSite placement.

Results

Twenty-one of 23 patients successfully completed brachytherapy after implantation, with only 2 (9%) requiring catheter removal secondary to unfavorable balloon positioning. There were no serious complications. Of 343 historical patients with breast cancer, 137 were intraoperative candidates for brachytherapy, but final postoperative histology disqualified 40 (29%).

Conclusions

Implantation of the MammoSite brachytherapy device is optimally performed postoperatively, after the final pathology is defined, utilizing ultrasound-guided percutaneous technique.

Keywords:  Breast cancer, Brachytherapy, Irradiation, MammoSite

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

PII: S0002-9610(03)00279-4

doi:10.1016/S0002-9610(03)00279-4

The American Journal of Surgery
Volume 186, Issue 4 , Pages 383-385, October 2003